<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943031</url>
  </required_header>
  <id_info>
    <org_study_id>IPTP-BTC</org_study_id>
    <nct_id>NCT02943031</nct_id>
  </id_info>
  <brief_title>The Effect of Individualized Precision Therapy Programs in Patients With BTC</brief_title>
  <official_title>The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled
      in this study. The samples of biliary tract tumors will be collected. Genome sequencing,
      mini-PDX and PDX will be performed according to the requirement of individualized precision
      therapy programs. Suitable drugs will be chose according to drug screening results. OS and
      PFS will be compared with traditional chemotherapy to evaluate the effect of individualized
      precision therapy programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective cohort study, patients who are eligible for inclusion criteria will
      enroll in the study. After bile duct tumor samples were collected, whole genome sequencing,
      drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided
      according to the different genomics classification, and then to develop individualized
      precise treatment programs.

      The investigators hope to achieve the following objectives:

      ① Through the establishment of Individualized Precision Therapy Programs to improve the
      overall survival of bile duct malignancy (BTC)；

      ② To study the molecular typing of the prognosis of biliary malignancy;

      ③ To construct a database of BTC gene bank, as well as for drug screening information.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Biliary Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>IPTP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Individualized Precision Therapy Programs</intervention_name>
    <description>After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.</description>
    <arm_group_label>IPTP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of biliary malignancies

          -  The expected survival time is longer than 3 months

          -  PKS score&gt; 60 points

          -  Willing to take part in the study

        Exclusion Criteria:

          -  Can not or refuse to collect tumor samples

          -  Refused to accept the relevant treatment method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JIAN WANG, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Biliary-pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Chen, M.D.</last_name>
    <phone>+8613601779874</phone>
    <email>dr_chentao78@163.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bile duct tumor</keyword>
  <keyword>individualized precise treatment programs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

